DABIGATRAN – THE NEW APPROACH FOR DEEP VENOUS TROMBOSIS PROPHYLAXIS
- 作者: Minasov T.B.1, Minasov B.S.1, Zagidullin S.Z.1, Zagidullin N.S.1, Caglayan E.2, Gassanov N.2
-
隶属关系:
- ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
- Университетская клиника внутренних болезней, г. Кёльн
- 期: 卷 17, 编号 3 (2011)
- 页面: 80-83
- 栏目: Experience exchange
- URL: https://journals.rcsi.science/2311-2905/article/view/125440
- DOI: https://doi.org/10.21823/2311-2905-2011-0-3-80-83
- ID: 125440
如何引用文章
全文:
详细
The amount of total joint replacement is more than 1.5 mln world wide and requirement is increasing each year. Nevertheless one of the most dramatic complication after orthopedic manipulations are deep venous trombosis. As known, two aspects of prophylaxis are most important: duration of treatment and the doses of drags. The aim of study was to analys the influence of dabigatran for the risk of postop complications with the short time patients treatment complains. Treatment combination with dabigatran was clinically effective and the rate of adversing events was low. Thus we can conclude that treatment complains of dabigatran significantly higher then traditional injections of low molecular weight heparins.
作者简介
T. Minasov
ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
编辑信件的主要联系方式.
Email: m004@yandex.ru
к.м.н., доцент кафедры травматологии и ортопедии 俄罗斯联邦
B. Minasov
ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
Email: fake@neicon.ru
профессор, заведующий кафедрой травматологии и ортопедии 俄罗斯联邦
Sh. Zagidullin
ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
Email: fake@neicon.ru
профессор, заведующий кафедрой пропедевтики внутренних болезней
俄罗斯联邦N. Zagidullin
ГБОУ ВПО «Башкирский государственный медицинский университет Росздрава», г. Уфа
Email: fake@neicon.ru
профессор кафедры пропедевтики внутренних болезней 俄罗斯联邦
E. Caglayan
Университетская клиника внутренних болезней, г. Кёльн
Email: fake@neicon.ru
старший ординатор 德国
N. Gassanov
Университетская клиника внутренних болезней, г. Кёльн
Email: fake@neicon.ru
ординатор 德国
参考
- Blech, S. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans / S. Blech [et al.] // Drug. Metab. Dispos. – 2008. – Vol. 36. – P. 386–399.
- Cohen, A.T. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study / A.T. Cohen [et al.] // Lancet. – 2008. – Vol. 371. – P. 387–394.
- Connolly, S.J. Dabigatran versus warfarin in patients with atrial fibrillation / S.J. Connolly [et al.] // N. Engl. J. Med. – 2009. – Vol. 361. – P. 1139–1151.
- Eriksson, B.I. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial / B.I. Eriksson [et al.] // J. Thromb. Haemost. – 2007. – Vol. 5. – P. 2178–2185.
- Eriksson, B.I. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, noninferiority trial / B.I. Eriksson [et al.] // Lancet. – 2007. – Vol. 370. – P. 949–956.
- Hirsh, J. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range / J. Hirsh [et al.] // Chest. – 2001. – Vol. 119. – P. 8S–21S.
- Liesenfeld, K.H. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis / K.H. Liesenfeld [et al.] // Br. J. Clin. Pharmacol. – 2006. – Vol. 62. – P. 527–537.
- Hip fracture outcomes in people age fifty and over. Background paper, Office of Technology Assessment. Washington, DC: US GPO, 2004.
补充文件
